Ezetimibe: Its Novel Effects on the Prevention and the Treatment of Cholesterol Gallstones and Nonalcoholic Fatty Liver Disease

Overview

Journal J Lipids

Publisher Wiley

Date 2011 Dec 2

PMID 22132342

Citations 16

Authors

Ornella de Bari

Brent A Neuschwander-Tetri

Min Liu

Piero Portincasa

David Q-H Wang

Affiliations

Soon will be listed here.

Abstract

The cholesterol absorption inhibitor ezetimibe can significantly reduce plasma cholesterol concentrations by inhibiting the Niemann-Pick C1-like 1 protein (NPC1L1), an intestinal sterol influx transporter that can actively facilitate the uptake of cholesterol for intestinal absorption. Unexpectedly, ezetimibe treatment also induces a complete resistance to cholesterol gallstone formation and nonalcoholic fatty liver disease (NAFLD) in addition to preventing hypercholesterolemia in mice on a Western diet. Because chylomicrons are the vehicles with which the enterocytes transport cholesterol and fatty acids into the body, ezetimibe could prevent these two most prevalent hepatobiliary diseases possibly through the regulation of chylomicron-derived cholesterol and fatty acid metabolism in the liver. It is highly likely that there is an intestinal and hepatic cross-talk through the chylomicron pathway. Therefore, understanding the molecular mechanisms whereby cholesterol and fatty acids are absorbed from the intestine could offer an efficacious novel approach to the prevention and the treatment of cholesterol gallstones and NAFLD.

Citing Articles

The Impact of Metabolic Factors and Lipid-Lowering Drugs on Common Bile Duct Stone Recurrence after Endoscopic Sphincterotomy with Following Cholecystectomy.

Wang S, Wu C, Sung K, Tsou Y, Lin C, Lee C J Pers Med. 2023; 13(10).

PMID: 37888101 PMC: 10608674. DOI: 10.3390/jpm13101490.

Metabolic dysfunction-associated gallstone disease: expecting more from critical care manifestations.

Portincasa P, Di Ciaula A, Bonfrate L, Stella A, Garruti G, Lamont J Intern Emerg Med. 2023; 18(7):1897-1918.

PMID: 37455265 PMC: 10543156. DOI: 10.1007/s11739-023-03355-z.

Recent advances in understanding and managing cholesterol gallstones.

Di Ciaula A, Portincasa P F1000Res. 2018; 7.

PMID: 30345010 PMC: 6173119. DOI: 10.12688/f1000research.15505.1.

Peroxisome Proliferator-Activated Receptor- Prevents Cholesterol Gallstone Formation in C57bl Mice by Regulating Bile Acid Synthesis and Enterohepatic Circulation.

Wang G, Han T, Wang S, Chen M, Sun Y, Fu Z Biomed Res Int. 2018; 2018:7475626.

PMID: 30105244 PMC: 6076980. DOI: 10.1155/2018/7475626.

Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats.

Al Zarzour R, Ahmad M, Asmawi M, Kaur G, Ahmed Saeed M, Al-Mansoub M Nutrients. 2017; 9(7).

PMID: 28718838 PMC: 5537880. DOI: 10.3390/nu9070766.

References

Zuniga S, Molina H, Azocar L, Amigo L, Nervi F, Pimentel F . Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int. 2008; 28(7):935-47. DOI: 10.1111/j.1478-3231.2008.01808.x. View

Diehl A . Epidemiology and natural history of gallstone disease. Gastroenterol Clin North Am. 1991; 20(1):1-19. View

Tiniakos D, Vos M, Brunt E . Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010; 5:145-71. DOI: 10.1146/annurev-pathol-121808-102132. View

Uyeda K, Repa J . Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 2006; 4(2):107-10. DOI: 10.1016/j.cmet.2006.06.008. View

Dujovne C, Bays H, Davidson M, Knopp R, Hunninghake D, Stein E . Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol. 2001; 41(1):70-8. DOI: 10.1177/00912700122009854. View

Chang T, Chang C . Ezetimibe blocks internalization of the NPC1L1/cholesterol complex. Cell Metab. 2008; 7(6):469-71. DOI: 10.1016/j.cmet.2008.05.001. View

Duan L, Wang H, Wang D . Cholesterol absorption is mainly regulated by the jejunal and ileal ATP-binding cassette sterol efflux transporters Abcg5 and Abcg8 in mice. J Lipid Res. 2004; 45(7):1312-23. DOI: 10.1194/jlr.M400030-JLR200. View

Buhman K, Accad M, Novak S, Choi R, Wong J, Hamilton R . Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat Med. 2000; 6(12):1341-7. DOI: 10.1038/82153. View

Bays H, Moore P, Drehobl M, Rosenblatt S, Toth P, Dujovne C . Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001; 23(8):1209-30. DOI: 10.1016/s0149-2918(01)80102-8. View

10.

Janowski B, Willy P, Devi T, Falck J, Mangelsdorf D . An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996; 383(6602):728-31. DOI: 10.1038/383728a0. View

11.

Davies J, Levy B, Ioannou Y . Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics. 2000; 65(2):137-45. DOI: 10.1006/geno.2000.6151. View

12.

Wang D, Cohen D, Carey M . Biliary lipids and cholesterol gallstone disease. J Lipid Res. 2008; 50 Suppl:S406-11. PMC: 2674701. DOI: 10.1194/jlr.R800075-JLR200. View

13.

Burnett D, Caplen M, Davis Jr H, Burrier R, Clader J . 2-Azetidinones as inhibitors of cholesterol absorption. J Med Chem. 1994; 37(12):1733-6. DOI: 10.1021/jm00038a001. View

14.

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004; 44(3):720-32. DOI: 10.1016/j.jacc.2004.07.001. View

15.

Hubscher S . Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006; 49(5):450-65. DOI: 10.1111/j.1365-2559.2006.02416.x. View

16.

Wang H, Wang D . Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine. Hepatology. 2005; 42(4):894-904. DOI: 10.1002/hep.20867. View

17.

INSULL Jr W, Koren M, Davignon J, Sprecher D, Schrott H, Keilson L . Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis. 2001; 157(1):137-44. DOI: 10.1016/s0021-9150(00)00615-8. View

18.

HAVEL R . Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol. 2000; 11(6):615-20. DOI: 10.1097/00041433-200012000-00008. View

19.

Mazer N, Carey M . Quasi-elastic light-scattering studies of aqueous biliary lipid systems. Cholesterol solubilization and precipitation in model bile solutions. Biochemistry. 1983; 22(2):426-42. DOI: 10.1021/bi00271a029. View

20.

Angulo P . Obesity and nonalcoholic fatty liver disease. Nutr Rev. 2007; 65(6 Pt 2):S57-63. DOI: 10.1111/j.1753-4887.2007.tb00329.x. View